Discovery of a Novel Series of Benzimidazoles/Purines as Potent, Selective and Orally Active Inhibitors of the DNA Polymerase Activity of POLQ
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c01990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Bernard Barlaam und 35 weiteren Autor:innen. Beteiligte Einrichtung: Oncology R&D, AstraZeneca, CambridgeCB2 0AA, U.K. Hauptthemen laut MEDLINE: DNA-Directed DNA Polymerase, Benzimidazoles, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
DNA polymerase θ (Polθ, gene POLQ) is a key enzyme in the microhomology-mediated end joining (MMEJ) pathway to repair DNA double strand breaks (DSB). Here we report the discovery of novel, potent, selective and orally active inhibitors of the DNA polymerase activity of POLQ. Starting from a weak inhibitor of POLQ (compound 1, IC50 0.8 μM, biochemical assay), further optimization of the series led to compound 37, a potent inhibitor of POLQ (IC50 < 0.003 μM, biochemical assay), which suppressed the cellular MMEJ pathway activity (IC50 0.10 μM), showed anti-proliferative activity in homologous recombination repair (HRR) deficient cell lines (e.g. BRCA2−/− DLD-1 IC50 0.058 μM), and enhanced antiproliferative activity of the PARP 1/2 inhibitor olaparib in multiple HRR defective cell lines, with no activity in HRR proficient settings. Compound 37 showed tumor regression in the BRCA2−/− DLD-1 murine xenograft model after chronic oral dosing in combination with olaparib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology R&D, AstraZeneca, CambridgeCB2 0AA, U.K.
- Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg431 83, Sweden.
- Discovery Sciences, R&D, AstraZeneca, CambridgeCB2 0AA, U.K.
- Protein Sciences, Structural Biology, and Biophysics, Discovery Sciences, R&D, AstraZeneca, CambridgeCB2 0AA, U.K.
- Oncology R&D, AstraZeneca, Gaithersburg, Maryland20878, United States.
- Oncology R&D, AstraZeneca, Waltham, Massachusetts02451, United States.
ORCID-Profile: Bernard Barlaam, Michael S Bodnarchuk, Ariamala Gopalsamy, Pamela A Lochhead, Alexander Pflug, Andy Pike, Christelle de Renty, Christina Vasalou, Jon J Winter-Holt
Zitieren
APA
Barlaam, B., Akrap, N., Barratt, D., Bodnarchuk, M. S., Cadogan, E. B., Caswell, S. J., Cook, K., Forment, J. V., Gopalsamy, A., Griffiths, D., Hughes, C., Lochhead, P. A., Longmire, D., Maia de Oliveira, T., Maresca, M., Moss, J. I., Peng, B., Pflug, A., Pike, A., …, & Zhang, K. (2026). Discovery of a Novel Series of Benzimidazoles/Purines as Potent, Selective and Orally Active Inhibitors of the DNA Polymerase Activity of POLQ. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01990
Vancouver
Barlaam B, Akrap N, Barratt D, Bodnarchuk MS, Cadogan EB, Caswell SJ, et al. Discovery of a Novel Series of Benzimidazoles/Purines as Potent, Selective and Orally Active Inhibitors of the DNA Polymerase Activity of POLQ. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01990
BibTeX
@article{Barlaam2026,
author = {Barlaam, Bernard and Akrap, Nina and Barratt, Derek and Bodnarchuk, Michael S and Cadogan, Elaine B and Caswell, Sarah Jane and Cook, Kimberly and Forment, Josep V and Gopalsamy, Ariamala and Griffiths, Daniel and Hughes, Craig and Lochhead, Pamela A and Longmire, David and Maia de Oliveira, Taiana and Maresca, Marcello and Moss, Jennifer I and Peng, Bo and Pflug, Alexander and Pike, Andy and de Renty, Christelle and Shields, Jason D and Shilliday, Fiona and Southgate, Harriet and Stubbs, Christopher J and Talapatra, Sandeep K and Turner, Oliver and Turner, Paul and Underwood, Elizabeth and Vasalou, Christina and Ware, Jamie and Winlow, Poppy and Winter-Holt, Jon J and Wrigley, Gail and Xue, Lin and Zhang, Jingrui and Zhang, Ke},
title = {Discovery of a Novel Series of Benzimidazoles/Purines as Potent, Selective and Orally Active Inhibitors of the DNA Polymerase Activity of POLQ},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01990}
}
EUVIMED